University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
145 articles with University of Texas MD Anderson Cancer Center
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer
Genprex, Inc. announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®)
Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies
New study will evaluate synergistic effect of Oncoprex gene therapy on checkpoint inhibition
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML).
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial.
Amgen, and The University of Texas MD Anderson Cancer Center, announced two multi-year collaborative research deals for a broad range of cancer therapeutics.
Bayer and MD Anderson Cancer Center Collaborate to Strengthen Oncology Translational Research and Clinical Development
Five-year agreement to accelerate early clinical development of selected Bayer drug candidates
Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Amgen and The University of Texas MD Anderson Cancer Center announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.
MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer
Optera Therapeutics will develop cancer cell therapies discovered at MD Anderson and apply Berkeley Lights' advanced cell therapy manufacturing systems with the goal of making these novel therapies accessible to all.
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy.
Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology
The collaborators plan to initiate a randomized, placebo-controlled clinical study at MD Anderson, sponsored by the Parker Institute, in patients with advanced metastatic melanoma.
University of Texas MD Anderson Cancer Center Release: Andrew Sabin Family Fellows To Receive $100,000 In Research Funding
American Dental Association And The University of Texas MD Anderson Cancer Center Announce Collaboration
Jiangsu Hengrui Medicine Co. Ltd. Enters Into Agreement With The University of Texas MD Anderson Cancer Center To Advance Immunotherapy And Precision Medicine For Cancer Treatment
Helsinn Healthcare SA,The University of Texas MD Anderson Cancer Center Enter Strategic Alliance To Improve Life Of Patients Conducting Clinical Studies In Cancer Supportive And Palliative Care
Karus Therapeutics Announces Strategic Collaboration With University of Texas MD Anderson Cancer Center
New York Businessman, Philanthropist Gives $30 Million To Research At The University of Texas MD Anderson Cancer Center